BioCryst Pharma (BCRX) Tops Q2 EPS by 14c ; Offers Guidance

BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of $0.15, $0.14 better than the analyst estimate of $0.01. Revenue for the quarter came in at $163.35 million versus the consensus estimate of $149.82 million.

GUIDANCE:

BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $608.4 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch